Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.

PharmacoEconomics
Tatia Chay WoodwardArthur Lazarus

Abstract

Bipolar I disorder (BPD I) is a recurrent illness that affects 1% of the US population and constitutes a large economic burden. However, few studies have investigated the cost effectiveness of maintenance treatment options for BPD I. To determine the cost effectiveness of maintenance treatment with quetiapine fumarate extended-release (XR) tablets in combination with mood stabilizers (lithium or divalproex) in comparison with the following treatments: placebo in combination with lithium or divalproex; no maintenance treatment; lithium monotherapy; lamotrigine monotherapy; olanzapine monotherapy; and aripiprazole monotherapy. The analysis was conducted from the societal and payer perspectives in the US, using a Markov model. The model simulated a cohort of 1000 stabilized BPD I patients and estimated the quarterly risk in three health states: euthymia, mania and depression. Efficacy data were derived from two randomized, double-blind trials comparing quetiapine + lithium/divalproex with placebo + lithium/divalproex for up to 2 years, as well as other published literature. Resource data were extracted from published literature. Drug costs, hospitalizations and physician visits were among the direct costs. Indirect costs included ...Continue Reading

References

Jun 1, 1994·Journal of Affective Disorders·R Sharma, H R Markar
Aug 10, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·R A HirthW G Weissert
Jul 24, 2001·PharmacoEconomics·C E BegleyL Bryant-Comstock
Apr 10, 2002·Journal of Health Economics·John BrazierMark Deverill
Jun 17, 2003·PharmacoEconomics·Leah KleinmanDennis Revicki
Nov 25, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseUNKNOWN Lamictal 605 Study Group
Nov 18, 2004·Journal of Affective Disorders·Lars Vedel Kessing, Povl Munk-Jørgensen
Jan 27, 2005·The Journal of Clinical Psychiatry·Jerónimo Saiz-RuizTeresa Díez
May 4, 2006·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Jun 24, 2006·Journal of Managed Care Pharmacy : JMCP·Neill W CalvertThomas R Thompson
Sep 2, 2006·The American Journal of Psychiatry·Ronald C KesslerPhilip S Wang
Dec 29, 2006·PharmacoEconomics·Rachael L Fleurence, Christopher S Hollenbeak
May 9, 2007·Archives of General Psychiatry·Kathleen R MerikangasRonald C Kessler
Aug 7, 2007·Expert Review of Neurotherapeutics·Roger S McIntyreJakub Z Konarski
Aug 8, 2007·Bipolar Disorders·Gregory E SimonJames Savarino
Jan 11, 2008·Primary Care Companion to the Journal of Clinical Psychiatry·Rachael L FleurenceKitty Rajagopalan
Oct 25, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Carlos FigueroaHelen Winter
Jun 2, 2009·Journal of Affective Disorders·A M Gonzalez-PintoF Fagnani
Sep 1, 2000·Acta Neuropsychiatrica·D J KupferA G Mailinger

❮ Previous
Next ❯

Citations

Apr 24, 2012·CNS Drugs·Mark Sanford, Gillian M Keating
May 9, 2012·PharmacoEconomics·Greg L Plosker
Jan 24, 2014·BMC Psychiatry·Jean LachaineMaud Beillat
May 20, 2015·Journal of Medical Economics·Krithika RajagopalanAntony Loebel
Jun 12, 2014·Bipolar Disorders·Anees Ahmed Abdul PariGuy M Goodwin
Apr 29, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Ather Muneer
Dec 24, 2014·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Joseph F LevyMarjorie A Rosenberg
Jul 31, 2018·Journal of Managed Care & Specialty Pharmacy·Erik J GroesslJorge A Garces
Sep 14, 2010·Advances in Therapy·Mario A Cristancho, Michael E Thase

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here